These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28432573)

  • 1. Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs.
    Butters J; Brown A; Griffith L; Kim S; Nicholls SJ
    Am J Cardiovasc Drugs; 2017 Dec; 17(6):447-452. PubMed ID: 28432573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL-C) lowering enough?
    Kostapanos MS; Katsiki N; Elisaf MS; Mikhailidis DP
    Curr Vasc Pharmacol; 2012 Mar; 10(2):173-7. PubMed ID: 22250844
    [No Abstract]   [Full Text] [Related]  

  • 4. The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials.
    Daida H; Dohi T; Fukushima Y; Ohmura H; Miyauchi K
    J Atheroscler Thromb; 2019 Jul; 26(7):592-600. PubMed ID: 31118346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of dyslipidemia and cardiovascular outcomes: the journey so far--is this the end for statins?
    Zoungas S; Curtis AJ; McNeil JJ; Tonkin AM
    Clin Pharmacol Ther; 2014 Aug; 96(2):192-205. PubMed ID: 24727468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total lipid management and residual risk: beyond statin therapy.
    Evans M
    Br J Hosp Med (Lond); 2011 Mar; 72(3):132-6. PubMed ID: 21475092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving lipid targets in primary care settings.
    Katsiki N; Athyros VG; Karagiannis A
    Curr Med Res Opin; 2014 Oct; 30(10):1971-4. PubMed ID: 25007308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond statins: lipid management to reduce cardiovascular risk.
    Schuck RN; Mendys PM; Simpson RJ
    Pharmacotherapy; 2013 Jul; 33(7):754-64. PubMed ID: 23606278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.
    Markossian T; Burge N; Ling B; Schneider J; Pacold I; Bansal V; Leehey D; Stroupe K; Chang A; Kramer H
    Am J Kidney Dis; 2016 Jun; 67(6):965-77. PubMed ID: 26943983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre.
    Chan RH; Chan PH; Chan KK; Lam SC; Hai JJ; Wong MK; Tam FC; Lam L; Chan CW; Lam YM; Siu DC; Tse HF; Lee SW
    Hong Kong Med J; 2012 Oct; 18(5):395-406. PubMed ID: 23018067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All at sea: new lipid-lowering drug trials continue to disappoint.
    Wierzbicki AS
    Int J Clin Pract; 2013 Jul; 67(7):595-8. PubMed ID: 23758438
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipid-lowering agents.
    Ewang-Emukowhate M; Wierzbicki AS
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):401-11. PubMed ID: 23811423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [From lipid target values to the JUPITER study. Significance of achieving lipid levels specified by the guidelines and deficiencies in practice].
    Márk L; Katona A
    Orv Hetil; 2009 Nov; 150(44):2012-8. PubMed ID: 19861287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent clinical studies of the effects of lipid-modifying therapies.
    Gotto AM; Moon JE
    Am J Cardiol; 2012 Jul; 110(1 Suppl):15A-26A. PubMed ID: 22697388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond statins: what to expect from add-on lipid regulating therapy?
    Laufs U; Weintraub WS; Packard CJ
    Eur Heart J; 2013 Sep; 34(34):2660-5. PubMed ID: 23832488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.